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Abstract
Background
Cytokines and chemokines in the tumor microenvironment drive metastatic development and
their serum levels might mirror the ongoing inflammatory reaction at the tumor site. Novel
highly sensitive tools are needed to identify colorectal cancer patients at high risk of recurrence
that should be more closely monitored during post-surgical follow up. Here we study whether
circulating inflammatory markers might be used to predict recurrence in CRC patients.
Methods
Circulating levels of the inflammatory cytokines IL-1, IL-6, IL-10, TNFalpha, CCL2, CXCL8,
VEGF and the acute phase protein Pentraxin-3 were measured by ELISA in preoperative
serum samples prospectively collected from a cohort of sixty-nine patients undergoing sur-
gical resection for stage 0–IV CRC and associated with post-operative disease recurrence.
Results
Cox multivariate analysis showed that combined high levels (ROC cut off-value) of
CXCL8, VEGF and Pentraxin3 were associated with increased risk of disease recurrence
[HR: 14.28; 95%CI: (3.13–65.1)] independently of TNM staging. Kaplan-Meier analysis
showed that CXCL8, VEGF and Pentraxin3 levels were significantly associated with worse
survival (P<0.001).
Conclusions
Circulating inflammatory mediators efficiently predicted postoperative recurrence after CRC
surgery. Therefore, this study suggest that their validation in large-scale clinical trials may
help in tailoring CRC post-surgical management.
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Introduction
Colorectal cancer (CRC) is a leading cause of cancer death in developed countries [1]. Despite
advances in diagnostic tests and surgical procedures that usually have curative intent, about
half of patients undergoing surgery for CRC with curative intent will experience metachronous
metastasis and consequent death [2]. To date pathological Nodal Metastasis Tumor System
(TNM) staging remains the benchmark for the prediction of CRC patients who will experience
disease progression, despite the core of the original Dukes system [3] is substantially
unchanged. In fact, histopathological staging lacks accuracy and an important percentage of
patients at greatest risk for disease recurrence are still not detected with this methodology [2]
[4]. Novel prognostic biomarkers of CRC would allow identification of subgroup of patients
with high risk of tumor relapse that should be considered for frequent surveillance, diagnostic
screening and therapeutic intervention.
It has been well established that inflammatory cells in the tumor microenvironment release
inflammatory mediators that in turn activate local immune networks to promote development
and growth of malignant cells by increasing their proliferation and survival as well as angiogen-
esis [5] [6] [7–9]. Besides, inflammatory mediators, i.e. chemokines together with angiogenic
factors are a trigger for the development of invasive abilities as they increase tumor cells motil-
ity and migration that ultimately results in metastatic occurrence [8]. The interconnection
between inflammation and angiogenesis is explained by the ability of VEGF and chemokine
such as CCL2 and CXCL8 to recruit leukocytes at the tumor site that in turn produce VEGF
and inflammatory mediators and thus amplify tumorigenic signal via an autocrine and para-
crine loop [8]. Chemokines and cytokines are extensively produced in the tumor microenvi-
ronment regardless of the initial triggers [8] and mediators such as IL-1b, TNFa and IL-6
directly promoted the tumor progression in experimental models of colorectal cancer [8, 10].
Inflammatory mediators detected in the serum of patients might mirror the ongoing inflam-
matory reaction at the tumor site. Consistently, population-based studies showed that individ-
uals with high circulating levels of inflammatory mediators are at greater risk for developing
CRC [11] [12, 13]. Thus, serum levels of these markers have the potential to become a para-
digm as non-invasive diagnostic tests for the detection of CRC patients [14]. However, few
studies on this issue assessed the ability of circulating inflammatory mediators to identify
patients who will develop postsurgical recurrences and metachronous metastasis with respect
to current clinical prognostic tools for CRC [15–17]. Therefore, well designed prospective stud-
ies are needed to better establish their clinical relevance.
In this study, we prospectively sampled preoperative plasma of CRC patients undergoing
surgical treatment at our Institution and we assessed whether the levels of cytokines and che-
mokines represented by IL-1, IL-6, IL-10, TNFalpha, CCL2, CXCL8, VEGF and the acute
phase protein Pentraxin-3 might be associated with postoperative disease recurrence in a
5-year follow-up study.
Material and Methods
Patient’s enrollment and study design
69 patients who were diagnosed with colorectal tumor, and consecutively underwent radical
surgery in Humanitas Research hospital with curative intent between April 2008 and August
2009 were included in this study. After patient gave informed consent to the investigation, a
blood sample from each patient was withdrawn at the time of hospital admission and before
surgery to be processed for plasma separation. Investigators who were blinded to the results of
the levels of immune parameters assembled a clinical database by collecting patients’
Inflammation and Colorectal Cancer Prognosis
PLOS ONE | DOI:10.1371/journal.pone.0148186 February 9, 2016 2 / 13
demographics, clinical and histopathological data that were recorded on the Institutional’s
Intranet server. Tumor clinical and histopathologic staging at diagnosis was determined in all
patients by combining histopathologic findings with surgical records and perioperative imag-
ing. Tumor staging was categorized according to the American Joint Committee on Cancer
AJCC guidelines. All the patient’s demographics, clinical and histopathological variables were
tested for covariance with levels of immune mediators (Table 1). These variables, together with
the amount of IL-1, IL-6, IL-10, TNFalpha, CCL2, CXCL8, VEGF and of the acute phase pro-
tein Pentraxin-3, were tested as predictors of patient’s outcome, to evaluate the likelihood of
tumor relapses with respect to the extent of blood levels of immune mediators. We defined the
outcome of CRC patients as a variable including any event (n = 9) of local tumor recurrences
(n = 1) or any metachronous distant-organ metastases (n = 8), which is named disease free sur-
vival (DFS). The survival of patients was calculated as disease specific survival (DSS) and con-
cerned any death related only to CRC disease (n = 5). To detect or exclude any postsurgical
tumor recurrences, patients underwent thoraco-abdominal computed-tomography, abdominal
ultrasonography, and chest radiography that were done according to common protocols for
surveillance. The observation period started immediately after the surgical procedure and the
detection of tumor recurrence or tumor related death was computed from diagnosis until data
were censored. The mean follow-up period of the cohort studied was 56.33 months
(SD = 15.74 months). If the death event was unrelated to CRC disease, time to follow-up was
stopped at the time of patient’s death which was not considered an event of outcome. Postsur-
gical tumor surveillance follow up data have not been available in 6 out of 69 patients (8.7%)
enrolled in the study and were therefore excluded from the outcome analysis according to pre-
vious guidelines [18]. Ethics Committee of the Humanitas Clinical and Research Center
approved the study, and the referring physician obtained written informed consent from each
patient prior to surgery.
Assays
Plasma samples were centrifuged at 3000 rpm for 10 minutes and then kept at -80°C until
ELISA assessment. Plasma levels of IL-1, IL-6, IL-10, TNFalpha, CCL2, CXCL8, VEGF were
determined by commercially available sandwich enzyme-linked immunosorbent assay (ELISA)
kit according to the manufacturer’s instructions. PTX3 in plasma was assayed with an “in
house” sandwich ELISA based on the monoclonal antibody MNB4 (capture antibody) and rab-
bit anti-serum (detection antibody) as previously described [19]. The detection limit is 100 pg/
ml and interassay variability is 8%-10%. Normal values of PTX3 are<2 ng/mL. The immune
mediators levels in the patients plasma samples were determined by correlating each value
duplicates to a standard curve based on a 2-fold serial dilution of recombinant IL-1, IL-6, IL-
10, TNFalpha, CCL2, CXCL8, VEGF and PTX3 with known concentration.
Statistical analysis
Statistical analysis was performed using Epi Info (Version 3.4.3), StatsDirect Statistical software
(Version 2.5) and GraphPad Prism software (Version 4.1). The association between immune
mediator values and patient’s baseline demographics, clinical and histopathological character-
istics and tumor features were estimated by linear regression analysis. To best determine the
association of each immune mediator and patient’s prognosis, a receiver operational curve
(ROC) analysis was performed. The ROC cut-off value of each continuous distribution was
defined to predict the occurrence of patient’s relapses. A Cox proportional hazard model was
developed to assess the ROC cut off value of IL-1, IL-6, IL-10, TNFalpha, CCL2, CXCL8,
VEGF and PTX3 and other demographic, clinical and histopathological features, in predicting
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the occurrence of DFS. To assess for confounders, Cox multivariate analysis was performed by
entering all the variables with a P value less than 0.20 at univariate analysis. By a backward
stepwise elimination approach, non-significant variables and their non-significant interactions,
were removed from the model. Kaplan-Meyer curves of DSS were plotted, while log-rank test
was used to compare the curves of each subgroup of CRC patients. For each test only two-sided
P values lower than 0.05 were considered statistically significant.
Results
Demographics and histopathological features of CRC patients included in this study and their
correlation with quantitative assessment of the preoperative plasma values of immune media-
tors are shown in Table 1. Subgroup analysis revealed that among all the immune mediators
only IL-1b and VEGF values slightly increased in advanced TNM staging (P = 0.06 and
P = 0.04, respectively) (Table 1). Interestingly, only IL-1b and TNFa values increased among
patients with high CEA blood levels (5ng/ml) at the cut-off generally employed for this bio-
marker, while other immune mediators were not associated with CEA levels (Table 1). Next,
we tested the linear correlation coefficients among continuous plasma values of inflammatory
markers as shown in Table 2. Linear regression analysis revealed that IL-1b correlated at a
great extent with TNF-a (r = 0.94, P<0.001) independently of other immune mediators
(Table 2). In addition, CXCL8 values independently linearly correlated with those of IL-6,
CCL2 and VEGF (r = 0.34, P = 0.006; r = 0.31 P = 0.01; r = 0.36 P = 0.003, respectively), while
IL-10 values linearly correlated only with those of VEGF (r = 0.39, P<0.001) independently of
the other immune markers (Table 1). Interestingly, the acute phase protein PTX3 levels did not
Table 1. IL-1, IL-6, CXCL8, IL10, CCL2, PTX-3, TNF-a and VEGF values in 69 stage 0-IV CRC patients according to demographics and histopatho-
logical features.
Median values
N (%) IL-1 IL-6 CXCL8 IL10 CCL2 PTX-3 TNF-a VEGF
All cases 69 (100)
Age
< 70 yrs. 26 0.52 4.69 7.19 5.77 38.41 5.69 13.04 37.59
 70 yrs. 43 0.40 5.86 6.64 5.60 38.81 7.00 10.89 31.92
Gender
Male 35 0.47 6.60 6.98 5.19 40.08 5.76 10.34 37.82
Female 34 0.48 4.95 6.49 6.00 37.12 6.40 11.69 29.33
TNM staging
0-I-II 40 0.44 5.25 5.92 5.31 40.52 5.95 11.17 29.33
III 24 0.40 5.71 6.82 5.84 38.23 6.92 10.47 39.15
IV 4 1.32a 12.81 11.48 30.83 40.99 5.02 18.20 106.17a
Tumor site
Colon 56 0.46 5.57 6.66 5.84 38.36 6.33 10.98 34.67
Rectum 13 0.54 5.86 6.79 4.14 42.13 5.13 11.54 30.78
CEA
<5ng/ml 42 0.32 4.24 6.79 5.08 38.31 6.20 9.93 31.97
5ng/ml 14 1.18 a 9.16 10.57 6.35 43.20 8.37 16.14 a 54.48
Mann Whitney analysis, IL-1, IL-6, CXCL8, IL10, CCL2, PTX-3, TNF-a and VEGF values were entered as dependent continuous variables.
a P<0.05
doi:10.1371/journal.pone.0148186.t001
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correlate with any of the immune markers studied (Table 1), suggesting that PTX3 might fol-
low different pathways of activation in CRC patients compared to other immune mediators.
Subsequently, we investigated the connection between baseline (preoperative) plasma levels
of immune mediators and the risk to develop postsurgical CRC recurrences. Continuous distri-
butions of patient’s plasma levels of circulating inflammatory mediators according to postsur-
gical CRC disease recurrence are shown in Fig 1. We found that patients who did not relapsed
(n = 54) had significantly lower plasma concentrations of IL-1 (P = 0.008), IL-6 (P = 0.01), IL-
10 (P = 0.04), CXCL8 (P0.001), VEGF (P0.001) and TNFalpha (P = 0.02) compared to
those who experienced recurrence of CRC disease (n = 9) (Fig 1). In contrast, CCL2 values did
not change according to the prognosis of CRC patients and the acute phase protein Pentraxin-
3 had only a tendency to increase (P = 0.11) among those patients who experienced postsurgi-
cal disease recurrence (Fig 1).
Consistent with prior studies [20], to obtain a reproducible and reliable method to bench-
mark the prognostic values of biomarkers, we calculated ROC curves for each immune markers
for CRC patients who had good prognosis (n = 54) versus those who experienced recurrence of
disease (n = 9) at follow up (S1 Fig). ROC plot model analysis revealed inflammatory mediators
with better sensitivity than specificity such as IL-1b (0.88 and 0.68), IL-6 (0.88 and 0.59), IL-10
(1 and 0.40), TNF-a (1 and 0.05), CCL2 (0.77 and 0.5), CXCL8 (1 and 0.64) and VEGF: (1 and
Table 2. Multiple regression analysis of IL-1, IL-6, CXCL8, IL10, CCL2, PTX-3, TNF-a and VEGF values in 69 stage 0-IV CRC patients.
Cytokines IL-1 a IL-6 a CXCL8 a IL-10 a CCL2 a PTX-3 a TNF-a a VEGF a
IL-1
rb -
P -
IL-6
rb 0.15 -
P 0.23 -
CXCL8
rb 0.03 0.34 -
P 0.79 0.006 -
IL-10
rb -0.01 0.06 -0.11 -
P 0.89 0.61 0.36 -
CCL2
rb -0.14 0.18 0.31 -0.01 -
P 0.25 0.14 0.01 0.99 -
PTX-3
rb 0.10 0.19 0.11 0.06 -0.06 -
P 0.41 0.13 0.36 0.60 0.63 -
TNF-a
rb 0.94 -0.05 -0.11 0.07 0.22 -0.12 -
P <0.001 0.68 0.38 0.57 0.08 0.33 -
VEGF
rb 0.11 -0.02 0.36 0.39 -0.05 -0.03 -0.10 -
P 0.36 0.88 0.003 0.001 0.64 0.81 0.43 -
a Multiple linear regression analysis model. Continuous values of IL-1, IL-6, CXCL8, IL10, CCL2, PTX-3, TNF-a and VEGF were entered as dependent
continuous variables.
b r = Correlation coefﬁcient.
doi:10.1371/journal.pone.0148186.t002
Inflammation and Colorectal Cancer Prognosis
PLOS ONE | DOI:10.1371/journal.pone.0148186 February 9, 2016 5 / 13
Fig 1. Continuous values of IL-1, IL-6, IL-10, TNF-a, CCL2, CXCL8, VEGF and the acute phase protein Pentraxin-3 in the plasma of colorectal
cancers according to the occurrence of postsurgical relapse. The amount of IL-1 (A), IL-6 (B), IL-10 (C), TNF-a (D), IL-8 (F), VEGF (G) significantly
increased in patients who experienced disease relapse, while the acute phase protein Pentraxin-3 (H) showed a tendency to associate with worse prognosis.
CCL2 (E) levels were not associated with disease relapse.
doi:10.1371/journal.pone.0148186.g001
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0.66) at the optimum cutoffs identified by the model (S1 Fig), while PTX-3 had higher specific-
ity that sensitivity (0.55 and 0.90) (S1 Fig). To improve our understanding of the prognostic
relevance of immune mediators, we designed a Cox univariate prognostic model (Table 2)
based on the threshold values identified by the ROC curve for each inflammatory marker. In
this model, CRC patients who had higher plasma levels (ROC value) of IL-1 (P = 0.01),
CXCL8 (P<0.001), IL-10 (P = 0.01), PTX3 (P = 0.002), IL-6 (P = 0.06), and VEGF (P<0.001)
associated with worse prognosis (Table 3), while higher levels of CCL2 (P = 0.31) and TNF-a
(P = 0.89) (Table 3) did not. Further, we tested for the independency of these biomarkers. To
avoid overfitting of the COX model [21, 22] because of the relatively low amount of events
(n = 9) in our cohort, each inflammatory mediator was separately entered in a multivariate
model including TNM stage or one other inflammatory mediator (data not shown). In these
models, we found that among all inflammatory mediators that were significant at univariate
analysis only CXCL8, CCL2 and VEGF values were independently and significantly associated
with prognosis (data not shown). In detail, high levels of CXCL8, VEGF and PTX-3 (ROC
value) identified subgroups of CRC patients [44.4% (28/63); 42.8% (27/63); 15.8% (10/63),
respectively] that efficiently detected disease recurrences [47.3% (9/19); 50.0% (9/18); 50.0%
(5/5)]. Thus, according to these results we combined the levels of CXCL8, VEGF and PTX-3
(ROC value of combined markers) (Table 4) and to adjust for confounders and to test its
prognostic independency, we performed a Cox multivariate analysis, with respect to demo-
graphics, clinical and histopathologic features (Table 4). Cox multivariate analysis showed that
higher levels of combined CXCL8, VEGF and PTX-3 (ROC values) associated with worse
prognosis [HR: 14.28, 95%CI (3.13–65.1), P<0.001] independently of TNM staging and other
variables included in this model (Table 4). Combined high cut-off of CXCL8, VEGF and PTX-
3 values was present only in 11% (7/63) of CRC patients, but this subgroup efficiently identified
71.4% (5/7) of relapsing cases. Conversely, a low cut-off of combined inflammatory values of
CXCL8, VEGF and PTX-3 identified a 38% (24/63) of CRC patients with 0% (0/24) of relapsing
cases. Overall, the predictive value to detect disease recurrences of the combined score of
CXCL8, VEGF and PTX-3 was better compared to each of their separate values (all P0.05).
Fig 2 shows the DSS curves of all investigated patients sub grouped by the plasma values of
CXCL8, VEGF, PTX-3 (ROC values) and the immune score. We found an association with
worse survival among CRC patients with values of CXCL8 (P = 0.008), VEGF (P = 0.001),
PTX-3 (P = 0.005) above the ROC threshold (ROC values). The immune score represented
by combined ROC values of CXCL8, VEGF and PTX-3 (low, medium, high cutoff) had the
ability to predict significantly worse survival (P<0.001) with a better efficiency compared to
single immune mediators.
Discussion
In this study, we showed that inflammatory mediators in the blood of CRC patients collected
prior to surgical resection might be candidate biomarkers to predict postsurgical progression
of CRC. By characterizing an array of different cytokines we had the possibility to benchmark
their prognostic relevance. We showed that CXCL-8, VEGF and the long Pentraxin 3 were the
best predictors of prognosis in our CRC study. In addition, a cytokine score based on the com-
bination of the levels of these immune mediators was independent of the conventional TNM
staging in identifying post-operative disease recurrences.
The present study followed the REMARK guidelines for the assessment of prognostic tumor
markers [23]. However, we acknowledge some weaknesses with the study design. First, we
quantified levels of inflammatory mediators before surgery but not during follow up. However,
previous studies showed that the levels of a common and unspecific systemic inflammatory
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marker as CRP did not change in individuals along the years [24, 25]. In addition, we quanti-
fied baseline levels of inflammatory mediators the day before surgery and for this reason the
type of surgical treatment does not represent a confounding variable as it cannot affect inflam-
matory mediator levels in our study. Second, we did not examine matched control healthy
blood donor since this was beyond the goal of this study. Third, we acknowledge the limited
amount of CRC patients included in our study might create overfitting prognostic models.
However, the number of events required to test independency of biomarkers is still debated
[22] and depends on the extent of the prognostic effect. The limited patient’s number of our
cohort rely on its prospective design and the short time span of patient’s enrollment, which
decrease selection biases and methodological inconsistencies usually associated with large ret-
rospective cohorts [26]. In addition, we employed ROC curve models to generate reproducible
data by measuring the specificity and sensitivity that are useful to benchmark the diagnostic
ability of biomarkers across studies [14].
To our knowledge, this is the first study to address the postsurgical prognostic relevance of
Pentraxin 3 in CRC. PTX3 is an immune mediator that belongs to the highly conserved family
Table 3. Cytokines as predictors of post-operative disease recurrence in 63 patients with stage 0-IV CRC.
Tumor Recurrence COX Analysis
no yes % H.R. (95%C.I.) P
All cases (N) 54 9 14.3
Cytokines values*
IL-1
Low 37 1 2.6 1.00 ref.
High 17 8 32.0 11.84 (1.47–95.39) 0.01
IL-6
Low 32 1 3.0 1.00 ref.
High 22 8 26.7 7.20 (0.87–59.24) 0.06
CXCL8
Low 35 0 0 1.00 ref.
High 19 9 32.1 N.A <0.001
IL-10
Low 22 0 0 1.00 ref.
High 32 9 22.0 NA 0.01
CCL2
Low 27 2 6.9 1.00 ref
High 27 7 20.6 2.27 (0.45–11.41) 0.31
PTX3
Low 49 4 7.5 1.00 ref
High 5 5 50.0 9.64 (2.24–41.42) 0.002
TNF-a
Low 51 8 13.6 1.00 ref
High 3 1 25.0 1.15 (0.13–10.13) 0.89
VEGF
Low 36 0 0 1.00 ref
High 18 9 33.3 NA <0.001
*Low and high cutoff values for each marker deﬁned by ROC curve analysis.
NA = not available.
doi:10.1371/journal.pone.0148186.t003
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of pentraxins, as well as C reactive protein (CRP) [27]. It has an important role in homeostatic
processes such as tissue remodeling, angiogenesis and inflammatory responses ([28], [27], [29]
and has been linked to the cancer-related inflammation [30]. In previous clinical studies, PTX3
was found to be increased in other tumors such as liposarcomas [31], glioma [32], lung [20]
and prostate cancer [33] compared to paired healthy controls [20, 33] or to benign hyperplasia
[33]. However, none of these studies linked PTX3 levels with postsurgical tumor relapses. In
addition, our array of cytokines was useful to investigate whether immune mediators correlate
with each other in the plasma of human CRC patients. The absence of covariance between Pen-
traxin-3 and other inflammatory mediators explain its independent impact on prognosis, and
further suggests that the combined inflammatory score might increase the detection yield of
postsurgical recurrences. Despite strong correlation between TNF-a and IL-1b, these mediators
associated with patient’s prognosis to a lesser extent than PTX3 levels, which suggests that
these cytokines might have a lower level of involvement in the metastatic relapse of CRC com-
paring to PTX3. In other studies, PTX3 was shown to be highly induced by LPS/TLRs [34, 35]
which can also induce the expression of CXCL8. In this context, it is important to acknowledge
that higher PTX3 and CXCL8 blood levels in patients with recurrence of disease in this study
Table 4. Predictors of post-operative disease recurrence in 63 patients with stage 0-IV CRC.
Tumor Recurrence COX Univariate analysis b COX Multivariate analysis a, b
No Yes H.R. (95%C.I.) P H.R. (95%C.I.) P
(n = 54) (n = 9)
Cytokine Score*
Low 24 0
Medium 28 4 11.51 (3.02–43.83) <0.001 16.21 (3.56–73.84) <0.001
High 2 5
Age
< 70 yrs. 23 2
 70 yrs. 31 7 2.67 (0.55–12.96) 0.22
Gender
Male 26 7
Female 28 2 0.37 (0.08–1.86) 0.23
TNM Staging
0-I-II 34 2
III 18 4 3.06 (1.24–7.57) 0.01 3.68 (1.21–11.20) 0.02
IV 1 3
NA 1 0
CEA
<5ng/ml 33 5
5ng/ml 8 4 1.47 (0.30–7.33) 0.64
NA 13 0
Tumor Site
Colon 44 7
Rectum 10 2 2.18 (0.57–8.31) 0.26
* Low and high cutoff values for each marker deﬁned by ROC curve analysis. Low cytokines score was deﬁned by combined lowIL-8-lowVEGF-lowPTX3
values. High score was deﬁned by combined highIL-8-highVEGF-highPTX3 values. Intermediate score was deﬁned by any other values.
a Multivariate COX regression analysis.
b Cytokine score, TNM staging, age and gender were included in the COX multivariate model. By a backward stepwise elimination approach, non-
signiﬁcant variables and their non-signiﬁcant interactions were removed from the model.
doi:10.1371/journal.pone.0148186.t004
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represent a mere phenomenological evidence of the inflammatory reaction at the tumor site.
Whether these mediators support the local metastatic process and their targeting would affect
CRC growth was beyond the aim of this study. Therefore, our data showing the upregulation of
serum PTX3 in metastatic CRCs patients is not conflicting with previous mechanistic reports
[36] and indeed provide further evidence that this mediator somehow is involved in the tumor-
igenic reaction.
Together with VEGF, which inhibitor is currently used as an antiangiogenic factor for the
treatment of stage IV CRC, CXCL8 is also a potent promoter of angiogenesis that can promote
vascularization at the tumor site, proliferation and metastasis of cancer cells and mediate
recruitment of tumor infiltrating leukocytes [37–39]. Additionally, our data confirm previous
findings on the prognostic abilities of circulating levels of VEGF [40, 41] and CXCL8 [42] in
CRC patients demonstrating that this type of methodology is highly reproducible.
Our data suggest that the introduction of circulating inflammatory mediators for detection
of post-surgical CRC progression would effectively identify individuals at high risk of recur-
rence independently of conventional risk predictors. CRC patients identified by high levels of
inflammatory mediator plasma levels should be monitored more closely in the follow up
regardless of their TNM status which would provide an additional tool in the decision-making
Fig 2. Kaplan—Meier curves showing disease-specific survival (DSS) after resection with curative intent for colorectal cancer according to
plasma values of IL-8, PTX-3, VEGF and the immune score. The ROC threshold values of IL-8, PTX3 and VEGF were calculated in the whole cohort (6.79
pg/ml, 31.97pg/ml, 6.29pg/ml, respectively) and were used as a cutoff to select high and low IL-8, PTX-3 and VEGF in colorectal cancer patients. Low
immune score was defined by combined lowIL-8-lowVEGF-lowPTX3 values. High immune score was defined by combined highIL-8-highVEGF-highPTX3
values. Intermediate score was defined by any other value. Values above the ROC cutoff were associated with worse patient’s survival for CXCL8
(P = 0.008), PTX3 (P = 0.001), VEGF (P = 0.005) and the immune score (P<0.001), compared to those below ROC cutoff.
doi:10.1371/journal.pone.0148186.g002
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process for the postsurgical screening. To conclude, PTX3 and CXCL8 plasma quantification
could be coupled with VEGF levels for getting the best yield of postsurgical recurrence detec-
tion from the blood samples. These findings, provide the rationale to design large scale clinical
studies in order to confirm the prognostic ability of these inflammatory mediators.
Supporting Information
S1 Fig. ROC-plot analysis curves comparing patients according to their postsurgical relapse
at the optimum cutoffs identified by the ROC model for all soluble immune mediators
studied. ROC plot curves at optimum cutoffs for each immune mediator were calculated and
tested for their ability to detect postsurgical tumor recurrences according to their sensitivity
and specificity. Sensitivity and Specificity: IL-1 (0,88 and 0,68); IL-6 (0,88 and 0,59); IL-10 (1
and 0,40); TNF-a (1 and 0,05); CCL2 (0,77 and 0,5); CXCL8 (1 and 0,64); VEGF: (1 and 0,66);
PTX-3: (0,55 and 0,90). ROC cut-off values: IL-1 (0,81 pg/ml), IL-6 (5,86 pg/ml), IL-10 (4,14
pg/ml), TNFa (49,72 pg/ml), CCL2 (38,03 pg/ml), CXCL8 (7,01 pg/ml), VEGF (39,03 pg/ml),
PTX3 (13,68 pg/ml).
(PDF)
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